Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker EXC
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Oct 30, 2026 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 30, 2026 | EXC Exelon Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 25, 2026 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 25, 2026 | EXC Exelon Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Jul 30, 2026 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jul 30, 2026 | EXC Exelon Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 6, 2026 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| May 6, 2026 | EXC Exelon Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 30, 2026 | EXC Exelon Corporation | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Apr 16, 2026 | EXC Exelon Corporation | 8.01 Other Events | 8-K | 8-K ↗ |
| Apr 16, 2026 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Feb 20, 2026 | EXC Exelon Corporation | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Feb 20, 2026 | EXC Exelon Corporation | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Feb 12, 2026 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Feb 12, 2026 | EXC Exelon Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Feb 3, 2026 | EXC Exelon Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K/A | 8-K ↗ |
| Dec 4, 2025 | EXC Exelon Corporation | 8.01 Other Events | 8-K | 8-K ↗ |
| Dec 4, 2025 | EXC Exelon Corporation | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Dec 4, 2025 | EXC Exelon Corporation | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Dec 4, 2025 | EXC Exelon Corporation | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Nov 26, 2025 | EXC Exelon Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Nov 24, 2025 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Nov 18, 2025 | EXC Exelon Corporation | 5.04 Temporary Suspension of Trading Under Employee Benefit Plans | 8-K | 8-K ↗ |
| Nov 4, 2025 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Nov 4, 2025 | EXC Exelon Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jul 31, 2025 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Jul 31, 2025 | EXC Exelon Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| May 5, 2025 | EXC Exelon Corporation | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| May 2, 2025 | EXC Exelon Corporation | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| May 1, 2025 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| May 1, 2025 | EXC Exelon Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Mar 10, 2025 | EXC Exelon Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Feb 21, 2025 | EXC Exelon Corporation | 2.03 Creation of a Direct Financial Obligation | 8-K | 8-K ↗ |
| Feb 21, 2025 | EXC Exelon Corporation | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Feb 19, 2025 | EXC Exelon Corporation | 8.01 Other Events | 8-K | 8-K ↗ |
| Feb 12, 2025 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Feb 12, 2025 | EXC Exelon Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Dec 3, 2024 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Dec 3, 2024 | EXC Exelon Corporation | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Oct 30, 2024 | EXC Exelon Corporation | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Oct 30, 2024 | EXC Exelon Corporation | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
41 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 4:40 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances